Thursday - February 26, 2026

Olena Medical Announces Continued Growth, Clinical Excellence, and Strategic Expansion in 2026

Dr. Paul Langevin, CEO – Olena Medical Leading anesthesia services provider sets new benchmarks in patient care, clinician partnerships, and healthcare innovation. Hackensack, NJ – February 26, 2026 – Olena Medical, a rapidly growing provider of anesthesia services and perioperative solutions, … Continue reading

Living Forever – AI Selected for Startup Grind Global Conference 2026 – Named Among Top 150 Startups Worldwide

AI-powered platform preserving living people’s personalities, voices, and stories earns exhibition and pitch slot at premier Silicon Valley startup event ATLANTA, GA – February 26, 2026 – Living Forever — AI, an Atlanta-based startup building fully interactive video AI digital twins … Continue reading

Primary Biliary Cholangitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Intercept Pharma, Enanta Pharma, COUR Pharma, Novartis, Gannex Pharma, Nanjing Chia-tai Tianqing Pharm

The Key Primary Biliary Cholangitis Companies in the market include – CymaBay Therapeutics, Inc., Zydus Therapeutics Inc., Gannex Pharma Co., Ltd., Nanjing Chia-tai Tianqing Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, COUR Pharmaceutical, Novartis, Merck, Mirum Pharmaceuticals, Inc., Genfit, CymaBay Therapeutics, Inc., … Continue reading

Obsessive Compulsive Disorder Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Biohaven Pharma, AbbVie, Biohaven Pharma, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche

The Key Obsessive Compulsive Disorder Companies in the market include – Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Pfizer, and others.   DelveInsight’s “Obsessive Compulsive Disorder Market Insights, Epidemiology, … Continue reading

Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pulmonary Fibrosis pipeline constitutes 110+ key companies continuously working towards developing 140+ Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading